M2-TAMs promote immunoresistance in lung adenocarcinoma by enhancing METTL3-mediated m6A methylation

BACKGROUND: Immunotherapy has become the first-line treatment for advanced non-small-cell lung cancer (NSCLC), but most patients still fail to benefit or have disease progression following treatment. M2 phenotype tumor-associated macrophages (M2-TAMs) are important cellular components in the immunos...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lige, Cheng, Daoan, Yang, Xin, Zhao, Weiqing, Fang, Cheng, Chen, Rui, Ji, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843413/
https://www.ncbi.nlm.nih.gov/pubmed/36660648
http://dx.doi.org/10.21037/atm-22-6104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843413/
https://www.ncbi.nlm.nih.gov/pubmed/36660648
http://dx.doi.org/10.21037/atm-22-6104

Ejemplares similares